Vertex Pharmaceuticals (VRTX) said pre-market Tuesday that the US Food and Drug Administration has accepted its New Drug Application (NDA) for the VX-445...
Moderna (MRNA) shares rose 7% in afternoon trade Wednesday after sharing a pipeline update and announced the extension of its agreement with Vertex (VRTX)....
Vertex Pharmaceuticals Inc's (NASDAQ:VRTX, Recent Price: 178.39) full year forecasted earnings estimates for 2019 and 2020 have been increased. The...
Q3, 2019, and 2020`s consensus estimates for Vertex Pharmaceuticals Inc (NASDAQ:VRTX, Recent Price: 179.29) have been revised upward. The Q3 earnings...
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
| Address | 50 Northern Avenue Boston, Massachusetts 02210 |
| Phone | +1.617.341.6100 |
| Number of Employees | 2,500 |
| Recent SEC Filing | 08/20/2019 4 |
| Chairman, President & Chief Executive Officer | Jeffrey M. Leiden |
| Chief Financial Officer & Executive Vice President | Charles F. Wagner |
| Chief Scientific Officer & EVP-Global Research | David Matthew Altshuler |
| Chief Medical Officer & Executive Vice President | Reshma Kewalramani |
| Price Open | $186.76 |
| Previous Close | $186.40 |
| 52 Week Range | $151.80 - 195.81 |
| Market Capitalization | $47.3 B |
| Shares Outstanding | 257.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/23/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 21.68 |
| Earnings per Share | $8.44 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.0 B |
| Net Profit Margin | 64.55% |
| Return on Equity | 51.71% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
